Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
3.470
-0.255 (-6.84%)
At close: Mar 9, 2026, 4:00 PM EDT
3.430
-0.040 (-1.15%)
After-hours: Mar 9, 2026, 6:53 PM EDT
Aditxt Revenue
Aditxt had revenue of $748.00 in the quarter ending September 30, 2025, a decrease of -89.09%. This brings the company's revenue in the last twelve months to $5.95K, down -97.20% year-over-year. In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%.
Revenue (ttm)
$5.95K
Revenue Growth
-97.20%
P/S Ratio
139.09
Revenue / Employee
$229
Employees
26
Market Cap
770.35K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.49M |
| Onconetix | 1.22M |
| Lyra Therapeutics | 600.00K |
| Biodexa Pharmaceuticals | 104.90K |
| Virax Biolabs Group | 2.99K |
ADTX News
- 4 days ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 - Business Wire
- 3 months ago - Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing - Business Wire
- 4 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Business Wire
- 4 months ago - Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Business Wire
- 5 months ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire
- 6 months ago - Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - PRNewsWire
- 6 months ago - Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - PRNewsWire
- 7 months ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire